Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia : therapeutic potential and challenges
Masterson, C. H. (Regenerative Medicine Institute, National University of Ireland)
Ceccato, Adrian (Hospital del Sagrat Cor (Barcelona, Catalunya))
Artigas Raventós, Antoni (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
dos Santos, C. (University of Toronto. Interdepartmental Division of Critical Care Medicine and Institutes of Medical Sciences)
Rocco, Patricia R. (National Institute of Science and Technology for Regenerative Medicine)
Rolandsson Enes, S. (Lund University. Department of Experimental Medical Science, Faculty of Medicine)
Weiss, D. J. (University of Vermont College of Medicine. Department of Medicine)
McAuley, D. (Queen's University Belfast. Wellcome-Wolfson Institute for Experimental Medicine)
Matthay, Michael A. (University of California. Cardiovascular Research Institute)
English, K. (Kathleen Lonsdale Institute for Human Health Research, Maynooth University)
Curley, G. F. (Royal College of Surgeons in Ireland. Anaesthesia, School of Medicine)
Laffey, John (Galway University Hospitals, Saolta University Hospital Group. Department of Anaesthesia and Intensive Care Medicine)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2021
Resum:	Severe viral pneumonia is a significant cause of morbidity and mortality globally, whether due to outbreaks of endemic viruses, periodic viral epidemics, or the rarer but devastating global viral pandemics. While limited anti-viral therapies exist, there is a paucity of direct therapies to directly attenuate viral pneumonia-induced lung injury, and management therefore remains largely supportive. Mesenchymal stromal/stem cells (MSCs) are receiving considerable attention as a cytotherapeutic for viral pneumonia. Several properties of MSCs position them as a promising therapeutic strategy for viral pneumonia-induced lung injury as demonstrated in pre-clinical studies in relevant models. More recently, early phase clinical studies have demonstrated a reassuring safety profile of these cells. These investigations have taken on an added importance and urgency during the COVID-19 pandemic, with multiple trials in progress across the globe. In parallel with clinical translation, strategies are being investigated to enhance the therapeutic potential of these cells in vivo, with different MSC tissue sources, specific cellular products including cell-free options, and strategies to 'licence' or 'pre-activate' these cells, all being explored. This review will assess the therapeutic potential of MSC-based therapies for severe viral pneumonia. It will describe the aetiology and epidemiology of severe viral pneumonia, describe current therapeutic approaches, and examine the data suggesting therapeutic potential of MSCs for severe viral pneumonia in pre-clinical and clinical studies. The challenges and opportunities for MSC-based therapies will then be considered.
Nota:	Altres ajuts: Science Foundation Ireland, 16-FRL-3845
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cell therapy ; Mesenchymal stem cells ; Pneumonia ; Coronavirus ; Influenza ; Acute respiratory distress syndrome ; Sepsis ; Critical illness ; Pandemic ; Acute hypoxic respiratory failure
Publicat a:	Intensive Care Medicine Experimental, Vol. 9 (december 2021) , ISSN 2197-425X

DOI: 10.1186/s40635-021-00424-5
PMID: 34970706

21 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d’Investigació i Innovació Parc Taulí (I3PT)
Articles > Articles de recerca
Articles > Articles publicats